Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
New England Journal of Medicine · 11.01.2024 · 390 (2) · 107-117
DOI: 10.1056/nejmoa2310234 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift New England Journal of Medicine, erschienen am 11.01.2024. Verfasst von Jeff S Healey und 37 weiteren Autor:innen. Beteiligte Einrichtung: From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the …. Hauptthemen laut MEDLINE: Anticoagulants, Aspirin, Atrial Fibrillation, Embolism. Die Arbeit wurde bisher 449-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Institute of Circulatory and Respiratory Health, Accelerating Clinical Trials Network Grant, Bristol-Meyers-Squibb/Pfizer Alliance.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. METHODS: We conducted a trial involving patients with subclinical atrial fibrillation lasting 6 minutes to 24 hours. Patients were randomly assigned in a double-blind, double-dummy design to receive apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of 81 mg daily. The trial medication was discontinued and anticoagulation started if subclinical atrial fibrillation lasting more than 24 hours or clinical atrial fibrillation developed. The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-treat population (all the patients who had undergone randomization); the primary safety outcome, major bleeding, was assessed in the on-treatment population (all the patients who had undergone randomization and received at least one dose of the assigned trial drug, with follow-up censored 5 days after permanent discontinuation of trial medication for any reason). RESULTS: We included 4012 patients with a mean (±SD) age of 76.8±7.6 years and a mean CHA2DS2-VASc score of 3.9±1.1 (scores range from 0 to 9, with higher scores indicating a higher risk of stroke); 36.1% of the patients were women. After a mean follow-up of 3.5±1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaban group (0.78% per patient-year) and in 86 patients in the aspirin group (1.24% per patient-year) (hazard ratio, 0.63; 95% confidence interval [CI], 0.45 to 0.88; P = 0.007). In the on-treatment population, the rate of major bleeding was 1.71% per patient-year in the apixaban group and 0.94% per patient-year in the aspirin group (hazard ratio, 1.80; 95% CI, 1.26 to 2.57; P = 0.001). Fatal bleeding occurred in 5 patients in the apixaban group and 8 patients in the aspirin group. CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the…
ORCID-Profile: Jeff S Healey, Shelagh B Coutts, Stuart J Connolly
Förderung
- Institute of Circulatory and Respiratory Health
- Accelerating Clinical Trials Network Grant
- Bristol-Meyers-Squibb/Pfizer Alliance
- Medtronic
- Population Health Research Institute
- Heart and Stroke Foundation of Canada
- Hamilton Health Sciences
- Canadian Stroke Prevention Intervention Network
Zitieren
APA
Healey, J. S., Lopes, R. D., Granger, C. B., Alings, M., Rivard, L., McIntyre, W. F., Atar, D., Birnie, D. H., Boriani, G., Camm, A. J., Conen, D., Erath, J. W., Gold, M. R., Hohnloser, S. H., Ip, J., Kautzner, J., Kutyifa, V., Linde, C., Mabo, P., …, & ARTESIA Investigators (2024). Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine, 390(2), 107-117. https://doi.org/10.1056/nejmoa2310234
Vancouver
Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine. 2024;390(2):107-117. doi:10.1056/nejmoa2310234
BibTeX
@article{Healey2024,
author = {Healey, Jeff S and Lopes, Renato D and Granger, Christopher B and Alings, Marco and Rivard, Lena and McIntyre, William F and Atar, Dan and Birnie, David H and Boriani, Giuseppe and Camm, A John and Conen, David and Erath, Julia W and Gold, Michael R and Hohnloser, Stefan H and Ip, John and Kautzner, Josef and Kutyifa, Valentina and Linde, Cecilia and Mabo, Philippe and Mairesse, Georges and Benezet Mazuecos, Juan and Cosedis Nielsen, Jens and Philippon, Francois and Proietti, Marco and Sticherling, Christian and Wong, Jorge A and Wright, David J and Zarraga, Ignatius G and Coutts, Shelagh B and Kaplan, Andrew and Pombo, Marta and Ayala-Paredes, Felix and Xu, Lizhen and Simek, Kim and Nevills, Sandra and Mian, Rajibul and Connolly, Stuart J and ARTESIA Investigators, ARTESIA Investigators},
title = {Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {2},
pages = {107--117},
doi = {10.1056/nejmoa2310234}
}
EUVIMED